Courtney Breen
Stock Analyst at Bernstein
(4.79)
# 547
Out of 5,134 analysts
321
Total ratings
94.8%
Success rate
27%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Courtney Breen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LLY Eli Lilly and Company | Maintained: Buy | $1,450 | $1,443.50 | +0.45% | 64 | Nov 16, 2026 | |
| AMGN Amgen | Rated: Hold | $345 → $400 | $465.67 | -14.10% | 33 | Nov 4, 2026 | |
| BMY Bristol-Myers Squibb Company | Reiterated: Hold | $61 | $63.43 | -3.83% | 34 | Nov 2, 2026 | |
| ABBV AbbVie | Reiterated: Hold | $225 → $230 | $295.03 | -22.04% | 30 | Oct 25, 2026 | |
| GILD Gilead Sciences | Reiterated: Buy | $160 | $168.08 | -4.81% | 32 | Oct 25, 2026 | |
| MRK Merck & Co. | Reiterated: Hold | $105 | $147.76 | -28.94% | 42 | Oct 25, 2026 | |
| MRNA Moderna | Reiterated: Hold | $45 | $223.37 | -79.85% | 45 | Oct 25, 2026 | |
| PFE Pfizer | Reiterated: Hold | $29 | $28.89 | +0.38% | 41 | Oct 25, 2026 |
Eli Lilly and Company
Nov 16, 2026
Maintained: Buy
Price Target: $1,450
Current: $1,443.50
Upside: +0.45%
Amgen
Nov 4, 2026
Rated: Hold
Price Target: $345 → $400
Current: $465.67
Upside: -14.10%
Bristol-Myers Squibb Company
Nov 2, 2026
Reiterated: Hold
Price Target: $61
Current: $63.43
Upside: -3.83%
AbbVie
Oct 25, 2026
Reiterated: Hold
Price Target: $225 → $230
Current: $295.03
Upside: -22.04%
Gilead Sciences
Oct 25, 2026
Reiterated: Buy
Price Target: $160
Current: $168.08
Upside: -4.81%
Merck & Co.
Oct 25, 2026
Reiterated: Hold
Price Target: $105
Current: $147.76
Upside: -28.94%
Moderna
Oct 25, 2026
Reiterated: Hold
Price Target: $45
Current: $223.37
Upside: -79.85%
Pfizer
Oct 25, 2026
Reiterated: Hold
Price Target: $29
Current: $28.89
Upside: +0.38%